|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ambros V: The functions of animal
microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lujambio A and Lowe SW: The microcosmos of
cancer. Nature. 482:347–355. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bartel DP: MicroRNAs: Target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
O'Day E and Lal A: MicroRNAs and their
target gene networks in breast cancer. Breast Cancer Res.
12:2012010. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Nam EJ, Yoon H, Kim SW, Kim H, Kim YT, Kim
JH, Kim JW and Kim S: MicroRNA expression profiles in serous
ovarian carcinoma. Clin Cancer Res. 14:2690–2695. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Jiang L, Huang Q, Zhang S, Zhang Q, Chang
J, Qiu X and Wang E: Hsa-miR-125a-3p and hsa-miR-125a-5p are
downregulated in non-small cell lung cancer and have inverse
effects on invasion and migration of lung cancer cells. BMC Cancer.
10:3182010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ferretti E, De Smaele E, Po A, Di
Marcotullio L, Tosi E, Espinola MS, Di Rocco C, Riccardi R,
Giangaspero F, Farcomeni A, et al: MicroRNA profiling in human
medulloblastoma. Int J Cancer. 124:568–577. 2009. View Article : Google Scholar
|
|
10
|
Hashiguchi Y, Nishida N, Mimori K, Sudo T,
Tanaka F, Shibata K, Ishii H, Mochizuki H, Hase K, Doki Y, et al:
Down-regulation of miR-125a-3p in human gastric cancer and its
clinicopathological significance. Int J Oncol. 40:1477–1482.
2012.PubMed/NCBI
|
|
11
|
Nishida N, Mimori K, Fabbri M, Yokobori T,
Sudo T, Tanaka F, Shibata K, Ishii H, Doki Y and Mori M:
MicroRNA-125a-5p is an independent prognostic factor in gastric
cancer and inhibits the proliferation of human gastric cancer cells
in combination with trastuzumab. Clin Cancer Res. 17:2725–2733.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Gerber HP, McMurtrey A, Kowalski J, Yan M,
Keyt BA, Dixit V and Ferrara N: Vascular endothelial growth factor
regulates endothelial cell survival through the
phosphatidylinositol 3′-kinase/Akt signal transduction pathway.
Requirement for Flk-1/KDR activation. J Biol Chem. 273:30336–30343.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Coultas L, Chawengsaksophak K and Rossant
J: Endothelial cells and VEGF in vascular development. Nature.
438:937–945. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Caron C, Spring K, Laramée M, Chabot C,
Cloutier M, Gu H and Royal I: Non-redundant roles of the Gab1 and
Gab2 scaffolding adapters in VEGF-mediated signalling, migration,
and survival of endothelial cells. Cell Signal. 21:943–953. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Elayappan B, Ravinarayannan H, Pasha SPBS,
Lee KJ and Gurunathan S: PEDF inhibits VEGF- and EPO- induced
angiogenesis in retinal endothelial cells through interruption of
PI3K/Akt phosphorylation. Angiogenesis. 12:313–324. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Radisavljevic Z, Avraham H and Avraham S:
Vascular endothelial growth factor up-regulates ICAM-1 expression
via the phosphatidylinositol 3 OH-kinase/AKT/Nitric oxide pathway
and modulates migration of brain microvascular endothelial cells. J
Biol Chem. 275:20770–20774. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gerhardt H, Golding M, Fruttiger M,
Ruhrberg C, Lundkvist A, Abramsson A, Jeltsch M, Mitchell C,
Alitalo K, Shima D, et al: VEGF guides angiogenic sprouting
utilizing endothelial tip cell filopodia. J Cell Biol.
161:1163–1177. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Adams RH and Alitalo K: Molecular
regulation of angiogenesis and lymphangiogenesis. Nat Rev Mol Cell
Biol. 8:464–478. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Herbert SP and Stainier DYR: Molecular
control of endothelial cell behaviour during blood vessel
morphogenesis. Nat Rev Mol Cell Biol. 12:551–564. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang X, Chen X, Fang J and Yang C:
Overexpression of both VEGF-A and VEGF-C in gastric cancer
correlates with prognosis, and silencing of both is effective to
inhibit cancer growth. Int J Clin Exp Pathol. 6:586–597.
2013.PubMed/NCBI
|
|
21
|
Zhao R, Liu XQ, Wu XP, Liu YF, Zhang ZY,
Yang GY, Guo S, Niu J, Wang JY and Xu KS: Vascular endothelial
growth factor (VEGF) enhances gastric carcinoma invasiveness via
integrin alpha(v)beta6. Cancer Lett. 287:150–156. 2010. View Article : Google Scholar
|
|
22
|
Peng Z, Wei D, Wang L, Tang H, Zhang J, Le
X, Jia Z, Li Q and Xie K: RUNX3 inhibits the expression of vascular
endothelial growth factor and reduces the angiogenesis, growth, and
metastasis of human gastric cancer. Clin Cancer Res. 12:6386–6394.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ji YN, Wang Q, Li Y and Wang Z: Prognostic
value of vascular endothelial growth factor A expression in gastric
cancer: A meta-analysis. Tumour Biol. 35:2787–2793. 2014.
View Article : Google Scholar
|
|
24
|
De Luca A, Lamura L, Gallo M, Maffia V and
Normanno N: Mesenchymal stem cell-derived interleukin-6 and
vascular endothelial growth factor promote breast cancer cell
migration. J Cell Biochem. 113:3363–3370. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yue X, Wang P, Xu J, Zhu Y, Sun G, Pang Q
and Tao R: MicroRNA-205 functions as a tumor suppressor in human
glioblastoma cells by targeting VEGF-A. Oncol Rep. 27:1200–1206.
2012.
|
|
26
|
Wen J, Zhao Y, Li J, Weng C, Cai J, Yang
K, Yuan H, Imperato-McGinley J and Zhu YS: Suppression of
DHT-induced paracrine stimulation of endothelial cell growth by
estrogens via prostate cancer cells. Prostate. 73:1069–1081. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Vacca A, Ria R, Ribatti D, Semeraro F,
Djonov V, Di Raimondo F and Dammacco F: A paracrine loop in the
vascular endothelial growth factor pathway triggers tumor
angiogenesis and growth in multiple myeloma. Haematologica.
88:176–185. 2003.PubMed/NCBI
|
|
28
|
Kinnaird T, Stabile E, Burnett MS, Lee CW,
Barr S, Fuchs S and Epstein SE: Marrow-derived stromal cells
express genes encoding a broad spectrum of arteriogenic cytokines
and promote in vitro and in vivo arteriogenesis through paracrine
mechanisms. Circ Res. 94:678–685. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Neviani P, Santhanam R, Oaks JJ, Eiring
AM, Notari M, Blaser BW, Liu S, Trotta R, Muthusamy N,
Gambacorti-Passerini C, et al: FTY720, a new alternative for
treating blast crisis chronic myelogenous leukemia and Philadelphia
chromosome-positive acute lymphocytic leukemia. J Clin Invest.
117:2408–2421. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
30
|
Qu J, Lu W, Li B, Lu C and Wan X: WWOX
induces apoptosis and inhibits proliferation in cervical cancer and
cell lines. Int J Mol Med. 31:1139–1147. 2013.PubMed/NCBI
|
|
31
|
Shao R, Xia W and Hung MC: Inhibition of
angiogenesis and induction of apoptosis are involved in
E1A-mediated bystander effect and tumor suppression. Cancer Res.
60:3123–3126. 2000.PubMed/NCBI
|
|
32
|
Su SJ, Yeh TM, Chuang WJ, Ho CL, Chang KL,
Cheng HL, Liu HS, Cheng HL, Hsu PY and Chow NH: The novel targets
for anti-angiogenesis of genistein on human cancer cells. Biochem
Pharmacol. 69:307–318. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Dallaglio K, Bruno A, Cantelmo AR,
Esposito AI, Ruggiero L, Orecchioni S, Calleri A, Bertolini F,
Pfeffer U, Noonan DM, et al: Paradoxic effects of metformin on
endothelial cells and angiogenesis. Carcinogenesis. 35:1055–1066.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zaytseva YY, Elliott VA, Rychahou P,
Mustain WC, Kim JT, Valentino J, Gao T, O'Connor KL, Neltner JM,
Lee EY, et al: Cancer cell-associated fatty acid synthase activates
endothelial cells and promotes angiogenesis in colorectal cancer.
Carcinogenesis. 35:1341–1351. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Lu C and Tanigawa N: Spontaneous apoptosis
is inversely related to intratumoral microvessel density in gastric
carcinoma. Cancer Res. 57:221–224. 1997.PubMed/NCBI
|
|
36
|
Hillen HF, Hak LE, Joosten-Achjanie SR and
Arends JW: Microvessel density in unknown primary tumors. Int J
Cancer. 74:81–85. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Li XJ, Ren ZJ and Tang JH: MicroRNA-34a: A
potential therapeutic target in human cancer. Cell Death Dis.
5:e13272014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Blandino G, Fazi F, Donzelli S, Kedmi M,
Sas-Chen A, Muti P, Strano S and Yarden Y: Tumor suppressor
microRNAs: A novel non-coding alliance against cancer. FEBS Lett.
588:2639–2652. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Maroof H, Salajegheh A, Smith RA and Lam
AKY: Role of microRNA-34 family in cancer with particular reference
to cancer angiogenesis. Exp Mol Pathol. 97:298–304. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Yan JW, Lin JS and He XX: The emerging
role of miR-375 in cancer. Int J Cancer. 135:1011–1018. 2014.
View Article : Google Scholar
|
|
41
|
Koukourakis MI, Giatromanolaki A, Sivridis
E, Gatter KC and Harris AL: High DLL4 expression in
tumour-associated vessels predicts for favorable radiotherapy
outcome in locally advanced squamous cell head-neck cancer (HNSCC).
Angiogenesis. 16:343–351. 2013. View Article : Google Scholar
|
|
42
|
Weidner N, Folkman J, Pozza F, Bevilacqua
P, Allred EN, Moore DH, Meli S and Gasparini G: Tumor angiogenesis:
A new significant and independent prognostic indicator in
early-stage breast carcinoma. J Natl Cancer Inst. 84:1875–1887.
1992. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Epstein RJ: VEGF signaling inhibitors:
More pro-apoptotic than anti-angiogenic. Cancer Metastasis Rev.
26:443–452. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Liu F, You X, Wang Y, Liu Q, Liu Y, Zhang
S, Chen L, Zhang X and Ye L: The oncoprotein HBXIP enhances
angiogenesis and growth of breast cancer through modulating FGF8
and VEGF. Carcinogenesis. 35:1144–1153. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Shih YP, Liao YC, Lin Y and Lo SH: DLC1
negatively regulates angiogenesis in a paracrine fashion. Cancer
Res. 70:8270–8275. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Kryza T, Achard C, Parent C, Marchand-Adam
S, Guillon-Munos A, Iochmann S, Korkmaz B, Respaud R, Courty Y and
Heuzé-Vourc'h N: Angiogenesis stimulated by human
kallikrein-related peptidase 12 acting via a platelet-derived
growth factor B-dependent paracrine pathway. FASEB J. 28:740–751.
2014. View Article : Google Scholar
|
|
47
|
Otrock ZK, Makarem JA and Shamseddine AI:
Vascular endothelial growth factor family of ligands and receptors
(review). Blood Cells Mol Dis. 38:258–268. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Hicklin DJ and Ellis LM: Role of the
vascular endothelial growth factor pathway in tumor growth and
angiogenesis. J Clin Oncol. 23:1011–1027. 2005. View Article : Google Scholar
|
|
49
|
Dayanir V, Meyer RD, Lashkari K and Rahimi
N: Identification of tyrosine residues in vascular endothelial
growth factor receptor-2/FLK-1 involved in activation of
phosphatidylinositol 3-kinase and cell proliferation. J Biol Chem.
276:17686–17692. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Pan Y, Wu Q, Qin L, Cai J and Du B: Gold
nanoparticles inhibit VEGF165-induced migration and tube formation
of endothelial cells via the Akt pathway. BioMed Res Int.
2014:4186242014. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Xu Y, Huang Z and Liu Y: Reduced
miR-125a-5p expression is associated with gastric carcinogenesis
through the targeting of E2F3. Mol Med Rep. 10:2601–2608.
2014.PubMed/NCBI
|
|
52
|
Bi Q, Tang S, Xia L, Du R, Fan R, Gao L,
Jin J, Liang S, Chen Z, Xu G, et al: Ectopic expression of MiR-125a
inhibits the proliferation and metastasis of hepatocellular
carcinoma by targeting MMP11 and VEGF. PLoS One. 7:e401692012.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Cao Y: VEGF-targeted cancer
therapeutics-paradoxical effects in endocrine organs. Nat Rev
Endocrinol. 10:530–539. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Jain RK: Antiangiogenesis strategies
revisited: From starving tumors to alleviating hypoxia. Cancer
Cell. 26:605–622. 2014. View Article : Google Scholar : PubMed/NCBI
|
